Published in World J Gastroenterol on December 28, 2016
Barrett's oesophagus: Current controversies. World J Gastroenterol (2017) 0.75
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst (2005) 8.90
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol (2008) 7.94
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA (2014) 4.89
Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst (2011) 4.31
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut (2013) 4.29
Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2009) 3.66
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy (2010) 3.12
The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut (2011) 2.51
Increasing incidence of Barrett's oesophagus in the general population. Gut (2005) 2.34
The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol (2008) 2.34
Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment Pharmacol Ther (2012) 2.20
Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut (2008) 2.08
Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol (2012) 1.96
Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol (2008) 1.85
Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol (2003) 1.73
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut (2010) 1.68
Meta analysis: Cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.50
Columnar-lined oesophagus without intestinal metaplasia: results from a cohort with a mean follow-up of 7 years. Aliment Pharmacol Ther (2012) 1.48
Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology (2011) 1.44
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol (2007) 1.31
Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol (2013) 1.29
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand J Gastroenterol (2008) 1.22
Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer (2012) 1.18
Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology (2011) 1.14
Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol (2012) 1.13
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer (2011) 1.00
Effects of dropping the requirement for goblet cells from the diagnosis of Barrett's esophagus. Clin Gastroenterol Hepatol (2012) 0.96
Increasing incidence of Barrett's oesophagus: a population-based study. Eur J Epidemiol (2011) 0.96
The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus. Aliment Pharmacol Ther (2011) 0.95
Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci (2007) 0.95
Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol (2012) 0.95
Routinely diagnosed low-grade dysplasia in Barrett's oesophagus: a population-based study of natural history. Histopathology (2009) 0.94
Projections for oesophageal cancer incidence in England to 2033. Eur J Cancer Prev (2011) 0.93
Treatment for Barrett's oesophagus. Cochrane Database Syst Rev (2010) 0.93
Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol (2007) 0.93
Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2012) 0.92
African Americans with Barrett's esophagus are less likely to have dysplasia at biopsy. Dig Dis Sci (2011) 0.89
A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol (1999) 0.87
The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer (2011) 0.87
Temporal trends of Barrett's oesophagus and gastro-oesophageal reflux and related oesophageal cancer over a 10-year period in England and Wales and associated proton pump inhibitor and H2RA prescriptions: a GPRD study. Eur J Gastroenterol Hepatol (2013) 0.86
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. Dis Esophagus (2010) 0.86
A systematic review and meta-analysis of the treatment for Barrett's esophagus. Dig Dis Sci (2008) 0.85
Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population. Int J Cancer (2013) 0.85
Are newly diagnosed columnar-lined oesophagus patients getting younger? Eur J Gastroenterol Hepatol (2009) 0.83
The relationship between smoking and severe dysplastic disease in patients with Barrett's columnar-lined oesophagus. Eur J Cancer Prev (2012) 0.83
Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus (2008) 0.82
Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. World J Gastroenterol (2014) 0.82
Barrett's oesophagus: Evidence from the current meta-analyses. World J Gastrointest Pathophysiol (2014) 0.82
Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. J Gastrointest Surg (2011) 0.81
Laparoscopic surgical treatment for patients with short- and long-segment Barrett's esophagus: which technique in which patient? Int Surg (2011) 0.77
The impact of the vitamins A, C and E in the prevention of gastroesophageal reflux disease, Barrett's oesophagus and oesophageal adenocarcinoma. Coll Antropol (2012) 0.76